Trial Profile.

<p>Trial Profile.</p

Pulmonary Exacerbations and Hospitalizations by Treatment Group - 24 Week Treatment Period.

<p>Pulmonary Exacerbations and Hospitalizations by Treatment Group - 24 Week Treatment Period.</p

Time to First Pulmonary Exacerbation Requiring Oral or Intravenous Antibiotics.

<p>Blue dashed line = placebo-treated patients. Black solid line = itraconazole-treated patients. The median time to first exacerbation was 77 days for the itraconazole group and 134 days for the placebo group, log-rank P = 0.35. Hash marks = censored observations.</p

Changes from Baseline in FEV1 Over the 48-Week Study.

<p>Blue dashed line = placebo-treated patients. Black solid line = itraconazole-treated patients. 95% confidence intervals are indicated by the error bars around the mean values.</p

Adverse Events.

<p>Adverse Events.</p

Baseline Characteristics of the Randomized Patients.

<p>Baseline Characteristics of the Randomized Patients.</p